Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
10 years of interferon beta-1b (Beta feron therapy.
Kappos L, Hartung HP. Kappos L, et al. Among authors: hartung hp. J Neurol. 2005 Sep;252 Suppl 3:iii1-iii2. doi: 10.1007/s00415-005-2009-z. J Neurol. 2005. PMID: 16170493 Review. No abstract available.
European validation of a standardized clinical description of multiple sclerosis.
Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C; Evaluation of the EDMUS system (EVALUED) Study Group. Amato MP, et al. Among authors: hartung hp. J Neurol. 2004 Dec;251(12):1472-80. doi: 10.1007/s00415-004-0567-0. J Neurol. 2004. PMID: 15645346
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Among authors: hartung hp. Ann Neurol. 2005 Dec;58(6):840-6. doi: 10.1002/ana.20703. Ann Neurol. 2005. PMID: 16283615 Review.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Kuhle J, et al. Among authors: hartung hp. N Engl J Med. 2007 Jan 25;356(4):371-8. doi: 10.1056/NEJMoa063602. N Engl J Med. 2007. PMID: 17251533 Free article. Clinical Trial.
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R; BENEFIT Study Group. Kappos L, et al. Among authors: hartung hp. Lancet. 2007 Aug 4;370(9585):389-97. doi: 10.1016/S0140-6736(07)61194-5. Lancet. 2007. PMID: 17679016 Clinical Trial.
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium. Farrell R, et al. Among authors: hartung hp. J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. J Int Med Res. 2008. PMID: 18230281 No abstract available.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Among authors: hartung hp. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
1,134 results